CCM
DYN icon

CAAS Capital Management’s Dyne Therapeutics DYN Stock Holding History

CAAS Capital Management’s Portfolio DYN Stock Details DYN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-21,636
Closed -$336K – 1103
2021
Q1 		$336K Sell
21,636
-164,275
-88% -$3.18M ﹤0.01% 993
2020
Q4 		$3.9M Buy
185,911
+174,911
+1,590% +$3.46M 0.04% 369
2020
Q3 		$222K Buy
+11,000
New +$241K 0.01% 434

Other funds holding DYN

MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VVA
Vida Ventures Advisors Boston, Massachusetts $29.4M AUM 93.58% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

CAAS Capital Management's DYN Position: Q2 2021 in Review

CAAS Capital Management sold out of Dyne Therapeutics (DYN) in Q2 2021, closing a stake of 21,636 shares — an estimated $336K sold.

CAAS Capital Management first reported a position in DYN in Q3 2020 and held it in 3 quarters. The position peaked at $3.9M in Q4 2020. 76 funds tracked by Wall St. Rank hold DYN as of Q2 2021.

  • CAAS Capital Management reported no remaining Dyne Therapeutics position as of Q2 2021 after selling out during the quarter.
  • CAAS Capital Management sold 21,636 Dyne Therapeutics shares in Q2 2021, an estimated $336K.
  • CAAS Capital Management first reported a position in Dyne Therapeutics in Q3 2020 and held it in 3 quarters.
  • CAAS Capital Management's Dyne Therapeutics position peaked at $3.9M in Q4 2020.
  • 76 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q2 2021.

Based on CAAS Capital Management's 13F filing for Q2 2021, filed 16 Aug 2021.